Advancing Immunotherapy: Insights from Ymmunobio CEO
In this discussion, Moe Alsumidaie interviews Peter Schiemann, CEO and Chairman of Ymmunobio, about the company’s innovative approaches to...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
In this discussion, Moe Alsumidaie interviews Peter Schiemann, CEO and Chairman of Ymmunobio, about the company’s innovative approaches to...
At SCOPE Summit Europe 2024, industry leaders gathered to explore the transformative potential of patient perspectives in decentralized clinical...
The UK’s Information Commissioner’s Office (ICO) recently issued a critical call for collaboration in genomics, emphasizing the need to...
In this insightful discussion, we interview Anthony Caggiano, Chief Medical Officer and Lisa Ricciardi, CEO, of Cognition Therapeutics about...
In this interview, we speak with Dr. Kuldip Dave from the ALS Association to explore their strategic approach to...
Virpax Pharmaceuticals has announced an extension of its research agreement with the National Center for Advancing Translational Sciences (NCATS),...
Everest Group has positioned eClinical Solutions as a Leader in Life Sciences Clinical Data and Analytics Platforms in their...
Narsoplimab, a first-in-class antibody targeting MASP-2, the effector enzyme of the complement lectin pathway, is under development for hematopoietic...
A recent multicenter, prospective randomized controlled clinical trial evaluated a new adaptive nomogram within the Aurora Xi Plasmapheresis System...
A groundbreaking study published in The Lancet Neurology demonstrates the ability of a novel synuclein seed amplification assay (synSAA)...